This round is no longer accepting investments, but others just like it are live now.

CLOSED

GET A PIECE OF XSURGICAL ROBOTICS

Surgical Robotics, Reinvented

XSurgical plans to take to market what Management believes to be the first surgical robot capable of both operating in hospitals and portable in the open field, integrating minimally invasive, open surgery and orthopedic procedures.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Company Image

REASONS TO INVEST

Reasons Icon

XSurgical is creating an entirely new market segment through the novel paradigm developing a robot capable of performing a wide variety of procedures reaching a bigger number of hospitals and open field applications.

Reasons Icon

We are aiming to serve about 3% of a $15 Billion market. Approximately $6 million of funding deployed into our company to date.

Reasons Icon

We believe XSurgical’s Robot is unique in that it is designed to be the first Open Architecture Surgical Robot, enabling third parties to implement their tools and procedures for our platform.

TEAM

Gianluca De Novi

Gianluca De Novi • Founder & Chief Executive Officer

Gianluca De Novi, Ph.D. A faculty member at the Harvard Medical School and Harvard Extension School, he earned his master’s degree in Electronics Engineering and his Ph.D. in robotics and control systems from the University of Bologna in Italy. While there, he also worked as researcher at the Laboratory of Automation and Robotics, the Computer Vision Laboratory and the Microelectronics Laboratory. After spending one year as a visiting researcher at the Bio-Robotics Laboratory of Harvard’s School of Engineering and Applied Sciences, he completed his Postdoctoral fellowship in Medical Device Design and Medical Simulation at the Department of Imaging at the Massachusetts General Hospital (now Massachusetts General Brigham) and became a Harvard Medical School faculty in Boston, MA. Dr. De Novi has also acted as scientific consultant to many leading corporations and research institutions. His interest in computer-based surgery began with exploration of cutting-edge technologies for graphic rendering and developing a complete virtual reality framework optimized for haptic rendering and surgical robotics. During his post-doctoral fellowship, he focused his interests on other crucial aspects of robotic surgery, such as real-time gesture analysis and task recognition, Human Machine Interaction and Augmented Reality. Through his academic position he has lead and participated to many important DoD funded research in this domain and contributed in the definition of upcoming standards in the Med-Tech field. He has been a scientific and strategic advisor at ADM Tronics Unlimited Inc. since May 2015 and served as a member of its Advisory Board since September 2014. Dr. De Novi is currently Chief Technical Officer (after a fast transition from an advisory appointment) at Plymouth Rock Technology, leading the development of Threat Detection technologies since February 2021, one more time developing technologies of interest for the US government. Among the many recognition that Dr. De Novi received during his career, stands out the PrimiDieci Society and the Italy-America Chamber of Commerce recognition of Dr. De Novi as one of the Top Ten most distinguished Italian Professionals in the United States under the age of 40 in 2013. Gianluca De Novi resides in Massachusetts.

Read More

Michele Marzola

Michele Marzola • Founder & Chairman of the Board

Michele Marzola is a serial entrepreneur with experience in more than 20 start-ups in Life Sciences that he founded and funded during the past 12 years. His experience ranges from medical devices to biotech. He was Chairman and President at Angiodroid, a company that he took to market leadership in peripheral angiographies through an innovative technology using Carbon Dioxide as contrast medium. Angiodroid consistently delivered triple digit growth under Michele’s leadership and was already profitable after three years from funding. At Green Bone Ortho Michele led a group of private investors to complete one of the largest Seed rounds in Italy and then led the Series A and Series B rounds for an aggregate value of € 30 M; Green Bone is now demonstrating its capability to regenerate bone even on large missing sections of several centimeters. At Interceptin Michele has co-founded a company developing a very promising therapy for prostate cancer and other solid tumors, based on an immunotoxin driven by a bispecific antibody fragment. At Surgica Robotica Michele led the company from its inception, achieving funding and development of the two first successful prototypes. Michele was previously General Manager at IBM, with responsibility of its consulting and application management services in Europe, Middle East and Africa; at IBM Michele also negotiated a JV with Enel S.p.A. and spearheaded the creation of intelligent networks around the globe. Mr. Marzola has an MBA with top honors from Columbia University in New York and an MSc in Mechanical Engineering with full grades from the University of Bologna in Italy. Michele Marzola resides in Italy.

Read More

Debora Botturi

Debora Botturi • Founder & Chief Scientific Officer

Dr. Debora Botturi, PhD, is an Executive with experience in innovation and technology transfer. Her experience is on Innovation and Communication Technologies (ICT) and her focus is on the application domain of robotic surgery. She received a master’s degree in Computer Science and a Ph.D. in Computer Science from the University of Verona with a specialization in teleoperation systems and automatic execution of robotic tasks. She was a post-doc at Dept. of Robotic and Mechatronic, DLR, Munich, Germany, and she was project manager of a ground breaking European Project on robotic surgery. Since 2013 she is an Innovation Manager carrying out research and supervision of industrial projects in the areas of robotics and advanced sensors and also an expert evaluator for the European Commission. Debora Botturi resides in Italy.

Read More

Overview


Surgical Precision Where it’s needed Most


XSurgical is committed to bringing the technology of robotic surgery to a whole new level. 


Our firm is currently developing a natively remotely controlled surgical robot employing AI - which can not only operate in a hospital like its competitors, but be deployed also in situations of disaster recovery and battlefields.  


*Images used in this video are in the prototype phase, the AI Surgical Robot is not currently available on the market.


This technology will bring the expertise and skills of a top surgeon to perform complex, surgical procedures in remote locations. 



Currently, we are working on the third iteration of our robot, the Gamma, at our laboratory in Cambridge MA.


All in all, we are here to move the technology forward. We are ready to bring that vision into an ever-expansive market. 


*Images used in this video are in the prototype phase, the AI Surgical Robot is not currently available on the market.


The Problem


Surgical Robots are Expensive and Limited


Today’s surgical robots are used only in the top 5,000 hospitals in the world. Those current vendors neglect the other 50,000 that have the same clinical needs of large hospitals - mostly because they cannot afford the costs of current solutions.


Not to mention, most robots today can perform only a very limited number of procedures. As a consequence, only the largest hospitals in major towns can ensure a steady volume of patients that can benefit from the technology, while the vast majority of the global population can not be reached (or would have to afford to go where it’s possible).



We believe XSurgical will deliver a more versatile solution that will enable more surgeons to execute more procedures with increased precision, filtered tremor, increased dexterity, scalable movements, and more (think about all the procedures where it is required the use of magnification lopes but the hands movement is not equally scaled).  


We believe that this will result in significant improvements in the overall quality of health care. 

The Market


Entering a Billion-Dollar Untapped Opportunity 


There is general consensus in the industry that the surgical robotic market should exceed $15 Billion globally at maturity. In fact, Bank of America Merrll Lynch is estimating that just the U.S. market alone should exceed $18 Billion - addressing more than 6 Million procedures per annum. (Source)



In addition to the initial capital equipment sale, we believe that the average value per unit sold is higher than $2 million, leading to a Total Addressable Market of more than $15 Billion. (Source)


*Images used in this video are in the prototype phase, the AI Surgical Robot is not currently available on the market.


XSurgical is uniquely positioned to serve this $ 1.6 Billion untapped opportunity. We plan to develop a new universal platform for surgical robotics that we believe will be the first able to serve both the Open Field and the 50,000 hospitals currently neglected by competitors.



The Solution


We Move the Technology, Not the Patients


XSurgical Gamma Robot is designed as a Universal Surgical Robot - capable of performing a high number of procedures just by adopting a proper set of instruments and tools. 


*Images used in this video are in the prototype phase, the AI Surgical Robot is not currently available on the market.


This enables the use of a single Robot to perform many different kinds of procedures, and it can be shared between multiple departments such as...



We believe XSurgical’s Robot is unique in that it is designed to be the first Open Architecture Surgical Robot. This means we enable third parties to implement their own procedures (Surgical Instruments, Software and Protocols) and sell their upgrades for our native platform (paying royalties for XSurgical). 


The idea is to “crowdsource” the effort of implementing a wide range of procedures. To further support its partners, XSurgical is implementing a XDK (XSurgical Development Kit) which includes mechanical drawings, electric diagrams, software to enable third parties to implement their procedures for our platform.



Our universal surgical robot is capable of:


  • Operating on both within hospitals and in the open field
  • Integrating both minimally invasive and open surgery procedures
  • Equally effective on soft tissues (e.g. abdominal) and hard tissues (e.g. orthopedics)
  • Creating an open platform enabling surgeons to use their preferred tools and systems on our robots
  • Making tele-operation real in both execution and supervision of surgical procedures
  • Enabling an effective sharing of assets among regional hospitals
  • Fast and easy deployment and set-up, enabling robotic execution for a much higher number of procedures
  • Significantly reducing the cost per robotic procedures thanks to better assets utilization and increased tool operating life
  • Making surgical robotics available and affordable for the vast majority of hospitals, including those in developing countries


We believe our Robot is the first and only to be designed for multiple types of surgery. Furthermore, we think our system will be the only surgical robot designed to operate not only in a hospital environment, but also for mobile settings.


*Images used in this video are in the prototype phase, the AI Surgical Robot is not currently available on the market.


The revenues will be generated by:

  • Robot sales
  • Service Maintenance
  • Disposable Instruments and parts
  • System extension packages
  • Third parties royalties

Why Invest


Our Vision is to Build Surgical Robots that Will Aid All Hospitals and Beyond


We believe we are 3 years away from the market. As a first step, we will be completing the prototypes that will be used for FDA approval and CE marking. We may be able to generate revenues earlier from military contracts, and within 10 years, we plan to be key players in a $15 billion industry. 


*Images used in this video are in the prototype phase, the AI Surgical Robot is not currently available on the market.


The surgical robots of the future have to be much easier to use -  capable of assisting a surgeon in speeding up their job, and avoid creating higher treatment costs. Also the convergence of AI means lower costs for high computation power, faster telecommunication networks, and more. 


*Images used in this video are in the prototype phase, the AI Surgical Robot is not currently available on the market.


We want to be pioneers in this field and deploy today smart and effective surgical robotic solutions and probably AI-supported surgical robots for the next decade.

ABOUT

HEADQUARTERS
701 Concord Ave, Ste 201
Cambridge, MA 02138
WEBSITE
View Site
XSurgical plans to take to market what Management believes to be the first surgical robot capable of both operating in hospitals and portable in the open field, integrating minimally invasive, open surgery and orthopedic procedures.

TERMS

XSurgical Robotics
Overview
PRICE PER SHARE
$4
DEADLINE
Apr. 21, 2022 at 6:59 AM UTC
VALUATION
$25M
FUNDING GOAL
$10K - $1.07M
Breakdown
MIN INVESTMENT
$100
MAX INVESTMENT
$1,070,000
MIN NUMBER OF SHARES OFFERED
2,500
MAX NUMBER OF SHARES OFFERED
267,500
OFFERING TYPE
Equity
SHARES OFFERED
Series A 1 Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.

Company Perks*

Early Bird

Friends and Family - First 72 hours | 15% bonus shares

Super Early Bird - Next 72 hours | 10% bonus

Early Bird Bonus - Next 7 days | 5% bonus shares

Volume

Tier 1 perk - ($1,000+ 1% bonus shares)

Tier 2 perk - ($5,000+ 2% bonus shares)

Tier 3 perk - ($10,000+ 3% bonus shares)

Tier 4 perk - ($25,000+ 5% bonus shares)

Tier 5 perk - ($50,000+ 10% bonus shares) and invitation to the Investors Club meetings, which will be held twice a year (virtually) with the participation of the Board and key advisors

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

XSurgical Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Preferred Stock at $4.00 / share, you will receive 10 additional shares of Common Stock, meaning you'll own 110 shares for $400. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Inter company debt or back payments. Salary payments made to one’s self, a friend or relative.

PRESS

Article Image
EIN Press Wire

XSurgical Hosts Officials. Department of Defense at Ribbon Cutting for new International HQ in Cambridge, Massachusetts.

Article Image
WCVB5

Bringing the skills of doctors to cutting edge robots. Cutting Edge Interview with Gianluca De Novi, PhD.

Article Image
MDDI Online

Where's Robotic-Assisted Surgery Headed? Innovators in surgical robotics shared their perspectives at MD&M East’s Medtech Education Hub.

Article Image
Dell Technologies

Remote-Controlled Robotic Surgery? Yup, It’s Happening.

Article Image
MDDI Online

XSurgical Touts MTEC Membership and Future in Surgical Robotics

ALL UPDATES

04.19.22

Final Day to Get your Shares of XSurgical Robotics

Time flies... it was a short ride and we have learned a lot.

Here we are, did you get a piece of our dream? if you did, get more... if you didn't this is the last opportunity to get some more on Start Engine.

We are excited for the new fellow shareholders that will follow us on our journey and we are looking forward to seeing more and more investors joining our mission.

Thank you to everyone.

Gianluca De Novi, Ph.D.

04.15.22

-5 to campaign ending!!!

- 5 days to the end of our crowdfunding campaign.

If you didn't get your shares, please do it! 

We are excited to close this campaign in a successful way.


Thanks,

XSurgical Robotics Team

04.14.22

Technical issues for the re-confirmation after campaign Extension

Dear Investors,

It appears to us that some of you didn't receive the request to reconfirm the initial investment in XSurgical when we extended our campaign with the direct result to have the investment canceled.

Please, be advised that if this is the case, the best course of action is to reconfirm the investment and contact Start Engine to inform them about the missed notification.

We sincerely apologize for these technical difficulties that together with some others have been contributing to the lack of timely communication and sometimes the loss of the investment. We are working with the team of Start Engine to ensure that there will be support for whoever suffered these circumstances.

Sincerely

XSurgical Robotics Team

03.30.22

XSurgical is accepting Investments again

Dear Investors,

We have extended our crowdfunding campaign for one more month. We thank each one of the investors that have reconfirmed the investment in XSurgical and we'll miss the ones that have changed their minds.


Thank you for continuing to support us,

XSurgical Robotics Team

03.17.22

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the XSurgical Robotics offering. Here's an excerpt describing the specifics of the change:

Issuer is extending campaign to 4/20/22.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

02.16.22

XSurgical Reaches $50K Milestone!

Greetings,

Big shoutout and thanks to our initial investors from the entire XSurgical Robotics team!

With your support, we just reached $50K on StartEngine in about 40 days since the beginning of our campaign.

That’s one good start and this will give to XSurgical the opportunity to reach even more investors.

Now, we’re ready to keep the ball rolling, reaching one by one all the development milestones!

Our mission is to try and advance the standard of care in surgical robotics with innovative technology solutions that can reach the entire global population rather than serve only those who live in proximity of large hospitals.


With your support, we know we can do it.

Become a shareholder today and let's democratize access to this technology!



02.08.22

XSurgical will attend the "Military Health System Research Symposium 2022"

The MHSRS is the Department of Defense’s foremost scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique research and development. The MHSRS is the premier military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter.

The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives falling under the topic areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, Medical Simulation and Information Sciences, Military Infectious Diseases, and the Radiation Health Effects.

The MHSRS is an annual four-day educational symposium that draws approximately 3,500 attendees.

At the current time, the management of XSurgical has decided to submit an abstract to the conference and to send some representatives to engage in networking, business development and meet the "old friends" maintaining the existing relationships sharing at the same time all the updates about the company and our technology development.

We are thrilled to be at MHSRS after two years of absence due to COVID cancellations.

01.01.22

Happy New Year!

I'd like to personally thank all the investors that joined us in these past few days of 2021. 

The year 2022 is going to be a very important year for us and we hope that our fundraising will be successful enough to allow us to move fast toward our final design of the Gamma Robot. 

We are proud to have you on board and we are looking forward to sharing any achievements with you.

We have ambitious goals but most importantly the determination, the motivation, and the passion for getting us through the finish line soon.


Have a wonderful 2022 guys!

Gianluca De Novi, PhD

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign reward.
Venture Club

Venture Club

Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).

$1,000

Tier 1 perk - 1% bonus shares

1% bonus shares

$5,000

Tier 2 perk - 2% bonus shares

2% bonus shares

$10,000

Tier 3 perk - 3% bonus shares

3% bonus shares

$25,000

Tier 4 perk - 5% bonus shares

5% bonus shares

$50,000

Tier 5 perk - 10% bonus shares

10% bonus shares) and invitation to the Investors Club meetings, which will be held twice a year (virtually) with the participation of the Board and key advisors

JOIN THE DISCUSSION

0/2500

DD
David DiLoreto

5 months ago

Would you be able to provide an update on how the company progressed in 2024 and any future expectations? Thank you for your time and any insights you can provide.

Show more

0

0

GC
Gianfilippo Cameli

3 years ago

What is happening with our investment? I never received either a refund or certificate of ownership. Can someone give us answers?

Show more

0

0

DM
David Macario

3 years ago

What is going on over there? Startengine is cancelling ALL investments, and nobody is fixing the issue. They REFUSE to respond to any emails. Do you even care that SE is tanking your raise? Can you fix this? What is the point of even trying to raise funds at this point if nobody cares?

Show more

2

0

JJ
Juan Jackson

3 years ago

SE has dropped the ball a lot here lately! I’ve missed several updates because they haven’t sent them out! And also they’ve given me some incorrect information. It’s quite frustrating.

Show more

0

1

JJ
Juan Jackson

3 years ago

My investment has been canceled according to SE and I did not cancel it! Does anyone know why this happens?

Show more

1

1

BK
Brian Kessler

3 years ago

Your getting very little traction on start engine. This sis a hot and crowded field right now although you show some differentiation you will need 100mm minimum to execute in the next three years. I just do see the belief in the product or process to get you there from the investment community. your best course of action may be to sell the IP and move on.

Show more

2

0

MN
Michael Nadler

3 years ago

How many degrees of freedom does the robot operating on the said to be patient have?

1

0

KT
Kirtson Thompson

3 years ago

I am in agreement with you about space travel (and remote locations in general) and the need for robotic assistance in medical procedures. How many degrees of freedom does your robot now have? How do you ensure the robot platform is safe and knows where its operating end is located at all times - or do you rely on the customer company to program this intelligence?

Show more

1

0

JJ
Juan Jackson

3 years ago

Do you have any backup plans in case you cannot meet your Start Engine crowdfunding goals? When did your fundraising start on SE?

Show more

2

0

SB
Stephen Blake

3 years ago

Hello, I would like, if possible, could you answer these two questions. I have read the reply from Gianluca D under the question by Vilem F. were as the company estimated being 3 years away from the civilian market. Question #1 There are 12 companies producing remote surgical robotics. How is XSurgical positioning itself long term to enter the civilian market? (Lower Pricing point than the competition) or is the focus to sell the product to various governments worldwide as part of their defense budget allocation? Question#2 In the US and worldwide, there are many remote hospital care facilities. This remote hospital location could deliver the same quality of health care of large urban and well-funded medical facilities through 5G technology. My concern is while the company is pushing the product for government use, which would provide a steady source of revenue, the real growth opportunity long term is the remote location. This product would have been perfect in Mayfield Kentucky and the other location hit by numerous tornados’; however, it was the various state national guards, not the US military was dispatched to aid in the disaster recovery. I am asking this question above because of the following. I received an Associate Degree in Electromechanical Engineering and Robotics in 1987 I was unable to work in the field of Robotics and spent the last 30+ years in Wireless communication For the past 20 years, I have for one the major wireless carrier expanding 5G technology in the US. I am a 12-year Member of IEEE

Show more

2

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

FAQ Timeline

WHY STARTENGINE?

Rewards Icon
REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

Lock Icon
SECURE

Your info is your info. We take pride in keeping it that way!

Ellipse Icon
DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

FAQS

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

MIN INVEST
$100
VALUATION
$25M

@ 2025 All Rights Reserved

Apple App Store Badge
Google Play Store Badge

Get To Know Us

Our Team

Careers

Blog

Let's Work Together

Raise Capital

Refer a Founder, earn $10k

Success Stories

Partnerships

Need Help

Contact Us

Help Center

Terms of Use

Privacy Policy

Disclaimer

Annual Reports

Form CRS

Reg. BI Disclosure

Terms of Use

Privacy Policy

Disclaimer

Annual Reports

Form CRS

Reg. BI Disclosure

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary LLC (“SE Primary”), a broker-dealer registered with the SEC and FINRA / SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system (ATS) regulated by the SEC and operated by SE Primary. SE Primary is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

StartEngine facilitates three types of primary offerings:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice concerning any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy, or completeness of any information. Neither StartEngine nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors

Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine Marketplace

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.

StartEngine Secondary (“SE Secondary”) is our investor trading platform. SE Secondary is an SEC-registered Alternative Trading System (“ATS”) operated by SE Primary that matches orders for buyers and sellers of securities. It allows investors to trade shares purchased through Regulation A+, Regulation Crowdfunding, or Regulation D for companies who have engaged StartEngine Secure LLC as their transfer agent. The term “Rapid,” when used in relation to transactions on SE Marketplace, specifically refers to transactions that are facilitated on SE Secondary, This is because, unlike with trades on the StartEngine Bulletin Board (“SE BB”), trades on SE Secondary are executed the moment that they are matched.

StartEngine Bulletin Board (“SE BB”) is a bulletin board platform on which users can indicate to each other their interest to buy or sell shares of private companies that previously executed Reg CF or Reg A offerings not necessarily through SE Primary. As a bulletin board platform, SE BB provides a venue for investors to access information about such private company offerings and connect with potential sellers. All investment opportunities on SE BB are based on indicated interest from sellers and will need to be confirmed. Even if parties express mutual interest to enter into a trade on SE BB, a trade will not immediately result because execution is subject to additional contingencies, including among others, effecting of the transfer of the shares from the potential seller to the potential buyer by the issuer and/or transfer agent. SE BB is distinct and separate from SE Secondary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. By contrast, under SE BB, SE Primary assists with the facilitation of a potential resulting trade off platform including, by among other things, approaching the issuer and other necessary parties in relation to the potential transaction. The term “Extended”, when used in relation to transactions on SE Marketplace denotes that these transactions are conducted via SE BB, and that these transactions may involve longer processing times compared to SE Secondary for the above-stated reasons.

Even if a security is qualified to be displayed on SE Marketplace, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine. It also does not constitute an endorsement, solicitation or recommendation by StartEngine. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, (2) assist in the determination of the fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.